Larimar Therapeutics, Inc. (LRMR) — Financial statements
Income statement, balance sheet, and cash flow for Larimar Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 154↑110.5% | 73↑164.8% | 28↑14.1% | 24↓36.8% | 38 | |
| General & Administrative Expenses | 18↑3.8% | 18↑25.0% | 14↑14.8% | 12↑1.7% | 12 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 18↑3.8% | 18↑25.0% | 14↑14.8% | 12↑1.7% | 12 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 172↑89.8% | 91↑117.7% | 42↑14.3% | 37↓27.6% | 50 | |
| Total Costs & Expenses | 172↑89.8% | 91↑117.7% | 42↑14.3% | 37↓27.6% | 50 | |
| Operating Results | ||||||
| Operating Income | -172↓89.8% | -91↓117.7% | -42↓14.3% | -37↑27.6% | -50 | |
| Depreciation & Amortization | 0.35↑10.1% | 0.32↑2.3% | 0.31↓2.2% | 0.32↓2.5% | 0.33 | |
| EBITDA | -172↓90.1% | -91↓118.5% | -41↓14.5% | -36↑27.8% | -50 | |
| EBIT | -172↓89.8% | -91↓117.7% | -42↓14.3% | -37↑27.6% | -50 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 7↓33.7% | 10↑113.9% | 5↑310.7% | 1↑784.8% | -0.17 | |
| Income Before Tax | -166↓105.5% | -81↓118.1% | -37↓4.5% | -35↑30.2% | -51 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -166↓105.5% | -81↓118.1% | -37↓4.5% | -35↑30.2% | -51 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -166↓105.5% | -81↓118.1% | -37↓4.5% | -35↑30.2% | -51 | |
| Bottom-Line Net Income | -166↓105.5% | -81↓118.1% | -37↓4.5% | -35↑30.2% | -51 | |
| EPS (Basic) | -2.27↓72.0% | -1.32↓57.1% | -0.84↑36.8% | -1.33↑54.6% | -2.93 | |
| EPS (Diluted) | -2.27↓72.0% | -1.32↓57.1% | -0.84↑36.8% | -1.33↑54.6% | -2.93 | |
| Weighted Average Shares | 73↑19.1% | 61↑39.5% | 44↑70.4% | 26↑50.1% | 17 | |
| Weighted Average Diluted Shares | 73↑19.1% | 61↑39.5% | 44↑70.4% | 26↑50.1% | 17 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.